CRISPR-targeting produced a point mutation that results in the amino acid substitution of proline with leucine at position 921 (P921L), which is equivalent to P913L in human patients with midline brain defects. (J:296537)
查看原文 参与反馈
CRISPR-targeting produced a point mutation that results in the amino acid substitution of proline with leucine at position 921 (P921L), which is equivalent to P913L in human patients with midline brain defects. (J:296537)